133 related articles for article (PubMed ID: 19462475)
1. Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses.
Zhao HL; Xue C; Wang Y; Sun B; Yao XQ; Liu ZM
Eur J Pharm Biopharm; 2009 Jun; 72(2):405-11. PubMed ID: 19462475
[TBL] [Abstract][Full Text] [Related]
2. Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering.
Zhao HL; Yao XQ; Xue C; Wang Y; Xiong XH; Liu ZM
Protein Expr Purif; 2008 Sep; 61(1):73-7. PubMed ID: 18541441
[TBL] [Abstract][Full Text] [Related]
3. Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation.
Zhao HL; Xue C; Wang Y; Li XY; Xiong XH; Yao XQ; Liu ZM
J Biotechnol; 2007 Sep; 131(3):245-52. PubMed ID: 17698234
[TBL] [Abstract][Full Text] [Related]
4. [Expression in Pichia pastoris and properties of human serum albumin-interferon alpha2b chimera].
Chang SH; Gong X; Yang ZY; Wang TY; Ma GC; Ma QJ; Wu J
Sheng Wu Gong Cheng Xue Bao; 2006 Mar; 22(2):173-9. PubMed ID: 16607939
[TBL] [Abstract][Full Text] [Related]
5. Preparation and biological evaluation of a glycosylated fusion interferon directed to hepatic receptors.
Cai G; Jiang M; Zhang B; Zhou Y; Zhang L; Lei J; Gu X; Cao G; Jin J; Zhang R
Biol Pharm Bull; 2009 Mar; 32(3):440-3. PubMed ID: 19252292
[TBL] [Abstract][Full Text] [Related]
6. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
Ramon J; Saez V; Baez R; Aldana R; Hardy E
Pharm Res; 2005 Aug; 22(8):1374-86. PubMed ID: 16078148
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Pichia pastoris PMR1 gene decreases its folding capacity on human serum albumin and interferon-alpha2b fusion protein.
Zhao HL; Xue C; Wang Y; Duan QF; Xiong XH; Yao XQ; Liu ZM
Yeast; 2008 Apr; 25(4):279-86. PubMed ID: 18350526
[TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of a potent, long-lasting recombinant human serum albumin-interferon α1 fusion protein expressed in Pichia pastoris.
Tian S; Li Q; Yao W; Xu C
Protein Expr Purif; 2013 Aug; 90(2):124-8. PubMed ID: 23748141
[TBL] [Abstract][Full Text] [Related]
9. Balancing the pharmacokinetics and pharmacodynamics of interferon-α2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy.
Zhao HL; Xue C; Du JL; Ren M; Xia S; Liu ZM
Mol Pharm; 2012 Mar; 9(3):664-70. PubMed ID: 22224503
[TBL] [Abstract][Full Text] [Related]
10. Production of potent long-lasting consensus interferon using albumin fusion technology in Pichia pastoris expression system.
Naseem MU; Ahmed N; Khan MA; Tahir S; Zafar AU
Protein Expr Purif; 2020 Feb; 166():105509. PubMed ID: 31604114
[TBL] [Abstract][Full Text] [Related]
11. Development and use of enzyme-linked immunosorbent assays (ELISA) for the detection of protein aggregates in interferon-alpha (IFN-alpha) formulations.
Braun A; Alsenz J
Pharm Res; 1997 Oct; 14(10):1394-400. PubMed ID: 9358552
[TBL] [Abstract][Full Text] [Related]
12. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon.
Walker A; Dunlevy G; Rycroft D; Topley P; Holt LJ; Herbert T; Davies M; Cook F; Holmes S; Jespers L; Herring C
Protein Eng Des Sel; 2010 Apr; 23(4):271-8. PubMed ID: 20093262
[TBL] [Abstract][Full Text] [Related]
13. Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β.
Ji SI; Park JH; You HG; Chi HJ; Bang YW; Cha SH
Immunol Lett; 2019 Mar; 207():46-55. PubMed ID: 30684504
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein expressed in Pichia pastoris.
Huang YS; Chen Z; Yang ZY; Wang TY; Zhou L; Wu JB; Zhou LF
Eur J Pharm Biopharm; 2007 Sep; 67(2):301-8. PubMed ID: 17418549
[TBL] [Abstract][Full Text] [Related]
15. Development and biological activity of long-acting recombinant human interferon-α2b.
Zhang Q; Wang C; Ma F; Yao L; Gao H; Zhu L; Zheng L
BMC Biotechnol; 2020 Mar; 20(1):16. PubMed ID: 32169063
[TBL] [Abstract][Full Text] [Related]
16. Thermal stability of the WHO international standard of interferon alpha 2b (IFN-alpha 2b): application of new reporter gene assay for IFN-alpha 2b potency determinations.
Caserman S; Menart V; Gaines Das R; Williams S; Meager A
J Immunol Methods; 2007 Jan; 319(1-2):6-12. PubMed ID: 17196611
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Purification of Human Interferon Alpha-2b and Serum Albumin Using Bioprivileged Fluorinated Ionic Liquid-Based Aqueous Biphasic Systems.
Carvalho SF; Pereiro AB; Araújo JMM
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473998
[TBL] [Abstract][Full Text] [Related]
18. Development of a high performance size exclusion chromatography method to determine the stability of Human Serum Albumin in a lyophilized formulation of Interferon alfa-2b.
Qian J; Tang Q; Cronin B; Markovich R; Rustum A
J Chromatogr A; 2008 Jun; 1194(1):48-56. PubMed ID: 18258245
[TBL] [Abstract][Full Text] [Related]
19. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
[TBL] [Abstract][Full Text] [Related]
20. Interferon immunogenicity: technical evaluation of interferon-alpha 2a.
Hochuli E
J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S15-21. PubMed ID: 9241611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
